{
    "nct_id": "NCT04883242",
    "official_title": "Isa-CAPED MM: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "* Patients with relapsed or refractory multiple myeloma, with >= 1 prior therapy\n* Must have received prior lenalidomide therapy\n* Must have measurable disease, as defined by International Myeloma Working Group criteria, having one or more of the following:\n\n  * Serum M protein >= 0.5 g/dL\n  * Urine M protein >= 200 mg/24 hours\n  * Involved serum free light chain level >= 10 mg/dL with abnormal kappa/lambda ratio\n  * Measurable biopsy-proven plasmacytomas (>= 1 lesion has a single diameter >= 2 cm)\n  * Bone marrow plasma cells >= 30%\n* Age 18 years and older, and have the capacity to give informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Subjects should have resolution of any toxicities from prior therapy to grade =< 1 or baseline prior to enrollment (with the exception of peripheral neuropathy)\n* Subjects are required to have grade =< 2 peripheral neuropathy to enroll\n* Prior autologous stem cell transplant is allowed; patients must be >= 6 months post- autologous stem cell transplantation to enroll\n* Estimated glomerular filtration rate (eGFR) >= 20 ml/min\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN)\n* Total bilirubin =< 2 x ULN\n* Absolute neutrophil count (ANC) >= 1,000/uL\n* Platelets >= 50,000/uL\n* Hemoglobin >= 8 g/dL\n* Growth factor use or transfusions may be used to meet the eligibility requirement for ANC, platelets, and hemoglobin\n* Female patients of childbearing potential and male patients must agree to use 2 effective forms of contraception or continuously abstain from heterosexual intercourse during the period of therapy, and for 6 months after discontinuation of study treatment for females and 3 months after discontinuation of study treatment for males\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of clinically significant cardiovascular disease, including congestive heart failure New York Heart Association (NYHA) class 3-4, symptomatic ischemia, left ventricular ejection fraction < 40%, uncontrolled conduction abnormalities, myocardial infarction in last 6 months\n* Uncontrolled hypertension as determined by the principal investigator (PI) or designee\n* Active plasma cell leukemia or systemic amyloid light-chain (AL) amyloidosis\n* History of another primary malignancy that has not been in remission for at least 1 year\n\n  * However, the following diagnoses are eligible for inclusion: non-melanoma skin cancer, localized prostate cancer, superficial bladder cancer, cervical carcinoma in situ, on biopsy or any prior malignancy with an estimated > 90% 1-year cure rate per sponsor-investigator\n* For patients with chronic hepatitis B viral infection, the hepatitis B virus (HBV) polymerase chain reaction (PCR) must be undetectable on suppressive therapy\n* Patients with a history of Hepatitis C viral infection must have been treated and cured. For patients on treatment for hepatitis C, they are eligible if they have an undetectable hepatitis C virus (HCV) viral load\n* Subjects with active uncontrolled infection\n* Concurrent use of other anticancer agents or experimental treatments",
    "miscellaneous_criteria": ""
}